Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20?

ImmunityBio Inc. (NASDAQ:IBRX) is among the best US stocks to buy under $20. As of November 26, ImmunityBio Inc. (NASDAQ:IBRX) is a consensus Buy, with all analysts covering it assigning a Buy or equivalent rating. With a consensus 1-year median price target of $8, the stock has an upside of over 275%.

On November 13, Jason Kolbert, an analyst at D. Boral Capital, reaffirmed his ‘Buy’ rating on ImmunityBio, Inc. (NASDAQ:IBRX), with an unchanged price target of $24. This stance is in line with the analyst’s previous rating on November 5, 2025.

During the recent quarter, ImmunityBio, Inc. (NASDAQ:IBRX) reported a substantial increase in revenue, thanks to the commercial distribution of ANKTIV A, its lead product targeting non-muscle-invasive bladder cancer. With total revenue of $75 million for the nine months ended September 30, the company impressively surpassed the $7.2 million level in the same period in 2024.

Although revenue growth stole the spotlight, ImmunityBio, Inc. (NASDAQ:IBRX) found itself in the middle of financial challenges, having reported a net loss of $289.5 million for the nine-month period. Much of this loss is due to the company’s operating expenses, primarily R&D outflows. Throughout the earnings call, management highlighted its focus on ANKTIV A’s market expansion and development of immunotherapy and cell therapy products.

ImmunityBio, Inc. (NASDAQ:IBRX) is a California-based commercial-stage biotechnology company that engages in therapies to combat cancers and infectious diseases. With a mission to “conquer cancer,” the company leverages its collaborations with the National Cancer Institute, Serum Institute of India Private Limited, and BeiGene, Ltd.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.